Abstract: According to the subject invention, there is disclosed a method for treating a patient/subject having a spastic disorder, a convulsive disorder, pain or epilepsy which includes administering to the subject having any one of these conditions a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or compounds which yield gamma-aminobutyramide as an intermediate, a metabolite, or a by-product.

Abstract: This invention relates to compositions comprising co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (?)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.

Abstract: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

Abstract: Methods and compositions for inhibiting the production of exotoxins are disclosed. The compositions include an effective amount of an isoprenoid inhibitory compound to substantially inhibit the production of exotoxins by Gram positive bacteria.

Abstract: A solid mixture or aqueous solution of amoxicillin antibacterial agent with a material that aids in its dissolution in water to render it ingestive and palatable.

Abstract: Methods and solutions are provided for removal of the smear layer on prepared tooth and bone surfaces, especially in endodontic environments.

Abstract: The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

Abstract: The present invention relates to supplementing the diets to sows during the periods of gestation, lactation, and breeding by feeding L-carnitine and chromium. The supplementation enhances pork productivity by increasing the number of pigs born alive in the subsequent reproductive cycle. Sow diets of this invention include L-carnitine and L-carnitine salts and trivalent chromium salts, such as chromium picolinate and chromium nicotinate. L-Carnitine is generally added to the swine feed formulation in the amount of from about 20 to about 1500 ppm, and the trivalent chromium salt is generally added to the swine feed formulation in the amount of from about 20 ppb to about 1000 ppb. The invention also relates to supplemented sow diets and feed supplement formulation.

Abstract: The present invention is directed to compositions comprising pramipexole and the use of such compositions to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). As shown in FIG. 6B the mean +/? SEM serum 2,3-DHBA levels for the 12 ALS participants decreased significantly after pramipexole treatment.

Abstract: S-alkylsiothiouronium derivatives such as S-ethylisothiouronium diethylphosphate are used for the treatment of headaches, in particular, migraines, as well as for the prevention or treatment of nausea and vomiting. The compositions of the invention are also effective in preventing or alleviating emesis associated with migraines or other medical conditions such as chemotherapy or radiotherapy, as well as other symptoms of migraines including phonophobia and photophobia.

Abstract: The invention provides methods and compositions for treating erectile dysfunction. The methods include the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a vasoactive prostaglandin composition of a semi-solid consistency. The composition comprises a vasoactive prostaglandin, a penetration enhancer, a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N-substituted amino)-alkanoate ester, a (N-substituted amino)-alkanol alkanoate, or a mixture of these enhancers. The lipophilic compound may be an aliphatic C1 to C8 alcohol, aliphatic C2 to C30 ester, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system providing a buffered pH value for said composition in the range of about 3 to about 7.4.

Abstract: The present invention provides a method for preventing and treating gastrointestinal diseases such as dyspepsia, irritable bowel disease and chemotherapy-associated nausea by administering an antagonist or partial agonist of 5HT1a receptors.

Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.

Abstract: The present invention provides a method which provides for a faster absorption of pharmaceutically acceptable amines. The method provides a pharmaceutically acceptable amine in combination with a non-steroidal anti-inflammatory drug in a liquid form. A preferred embodiment employs pseudoephedrine and ibuprofen.

Abstract: The present invention concerns the use of 1-isopropyl-3-[(4-m-toluidino-3-pyridyl)sulphonyl]-urea in the pharmaceutical field. In particular, it proposes the use of a pure and stable polymorphic form of 1-isopropyl-3-[(4-m-toluidino-3-pyridyl)sulphonyl]-urea for the preparation of solid pharmaceutical forms, and likewise a method of synthesis to obtain such a pure and stable polymorphic form of 1-isopropyl-3-[(4-m-toluidino-3-pyridiyl)sulphonyl]-urea.

Abstract: This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of the bimodally-acting opioid agonist. The method of the present invention comprises administering to a subject an analgesic or sub-analgesic amount of a bimodally-acting opioid agonist such as morphine and an amount of an excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of the bimodally-acting opioid agonist and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of the bimodally-acting opioid agonist.

Abstract: The first embodiment of present invention provides a composition, which includes: (a) a photocatalytic titanium oxide or a photocatalytic titanium oxide precursor; (b) at least one selected from the group including: a silicon compound having the following formula (I): wherein X1, X2, X3 and X4 each independently represent an alkoxy group or a halogen atom, a hydrolyzate of the silicon compound (I), a silicone resin, silicone resin precursor and silica; and (c) a liquid medium. Another embodiment of the present invention provides a dental and oralogic composition, that includes a photocatalytic titanium oxide or a photocatalytic titanium oxide precursor. Another embodiment of the present invention provides a dental and oralogic composition, that includes a photocatalytic titanium oxide or a photocatalytic titanium oxide precursor, and a liquid medium.

Abstract: Treatment of normal, non-cancerous, animal cells with an agent that depletes polyamines within the cells results in an inhibition of apoptosis when the cells are exposed to an inducer of apoptosis. This inhibition of apoptosis is not observed, or is observed to a lesser extent, in similarly treated cancerous cells. The method of the invention is useful in obtaining preferential killing of cancer cells, as opposed to normal cells, due to anti-cancer therapy.

Abstract: The present invention relates to an oral composition containing a zinc compound containing free available zinc ion and at least one stabilized or stable Eh raising compound distributed in an oral vehicle. The present invention further relates to a method of inhibiting the formation of sulfur containing anions and preventing a reduction in the Eh of the oral cavity. A method of reducing oral malodor and gingivitis and periodontitis is also provided by this invention.

Abstract: Compositions of non-racemic mixtures of d- and l-methadone and a method of treating pain using the composition. The composition is especially useful for treating pain of mixed origin. For predominantly neuropathic pain, a mixture of predominantly d-methadone, up to about 90%, is used. For predominantly somatic pain, a mixture of predominantly l-methadone, up to about 90%, is used. The non-racemic mixture of d- and l-methadone may be further combined with a pharmacologically effective amount of a nonopioid component. In another aspect of the invention, the methadone can be combined with an opioid antagonist such as naloxone, naltrexone, or the like.